scholarly journals In vitro activity of taurolin against multiple antibiotic resistant strains of Gram-negative non-fermenters including Stenotrophomonas maltophilia and Achromobacter xylosoxidans from lung transplant patients

2008 ◽  
Vol 7 ◽  
pp. S46
Author(s):  
A. Nicholson ◽  
J.D. Perry ◽  
G. Short ◽  
S. Peart ◽  
F.K. Gould
Keyword(s):  
Stenotrophomonas Maltophilia ◽  
Lung Transplant ◽  
Vitro Activity ◽  
Achromobacter Xylosoxidans ◽  
In Vitro Activity ◽  
Antibiotic Resistant ◽  
Gram Negative ◽  
Transplant Patients ◽  
Resistant Strains

Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli

2020 ◽  
Vol 75 (9) ◽  
pp. 2609-2615 ◽  
Author(s):  
Yawei Zhang ◽  
Chunjiang Zhao ◽  
Qi Wang ◽  
Xiaojuan Wang ◽  
Hongbin Chen ◽  
...  
Keyword(s):  
Stenotrophomonas Maltophilia ◽  
Enterobacter Cloacae ◽  
Polymyxin B ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Negative ◽  
Carbapenem Resistant ◽  
Resistant Strains

Abstract Background SPR206 is a novel polymyxin analogue. Activity against clinical isolates is little documented. Methods A collection of 200 MDR, carbapenem-resistant, tigecycline-resistant, colistin-resistant and non-MDR clinical isolates of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae and Stenotrophomonas maltophilia was obtained from 50 centres across China (2016–17). All isolates were derived from respiratory tract, urine and blood samples. Strains were purposely selected on the basis of phenotypes, genotypes and specimen origins. MICs of SPR206 and other antimicrobials were determined. Results SPR206 was active against all bacteria tested except colistin-resistant isolates. The MIC50/90 values of SPR206 for colistin-resistant strains were comparable to known polymyxins (16/128 versus 8/128 mg/L). SPR206 exhibited potent activity against colistin-susceptible OXA-producing A. baumannii (MIC50/90 = 0.064/0.125 mg/L), NDM-producing Enterobacteriaceae (MIC50/90 = 0.125/0.25 mg/L) and KPC-2-producing Enterobacteriaceae (MIC50/90 = 0.125/0.5 mg/L). In fact, SPR206 was the most potent agent tested, with 2- to 4-fold lower MICs than colistin and polymyxin B for A. baumannii, P. aeruginosa and Enterobacteriaceae. Additionally, MIC values of SPR206 (MIC50/90 = 0.064/0.125 mg/L) were 16- to 32-fold lower than those of tigecycline (MIC50/90 = 2/2 mg/L) for tigecycline-susceptible carbapenem-resistant A. baumannii. Conclusions SPR206 showed good in vitro activity against MDR, tigecycline-resistant and non-MDR clinical isolates of Gram-negative pathogens. SPR206 also exhibited superior potency to colistin and polymyxin B, with 2- to 4-fold lower MIC50/90 values.

40: In Vitro Activity of Taurolin Against Filamentous Fungi Isolated from Lung Transplant Patients

2008 ◽  
Vol 27 (2) ◽  
pp. S74 ◽  
Author(s):  
A. Nicholson ◽  
S. Peart ◽  
C. Rennison ◽  
J.D. Perry ◽  
K.F. Gould
Keyword(s):  
Filamentous Fungi ◽  
Lung Transplant ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Transplant Patients

scholarly journals In vitro activity of para-guanidinoethylcalix[4]arene against susceptible and antibiotic-resistant Gram-negative and Gram-positive bacteria

2007 ◽  
Vol 60 (3) ◽  
pp. 575-581 ◽  
Author(s):  
Marion Grare ◽  
Maxime Mourer ◽  
Stéphane Fontanay ◽  
Jean-Bernard Regnouf-de-Vains ◽  
Chantal Finance ◽  
...  
Keyword(s):  
Vitro Activity ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Antibiotic Resistant ◽  
Gram Negative ◽  
Gram Positive Bacteria

scholarly journals In Vitro Activity of the Histatin Derivative P-113 against Multidrug-Resistant Pathogens Responsible for Pneumonia in Immunocompromised Patients

2005 ◽  
Vol 49 (3) ◽  
pp. 1249-1252 ◽  
Author(s):  
Andrea Giacometti ◽  
Oscar Cirioni ◽  
Wojciech Kamysz ◽  
Giuseppina D'Amato ◽  
Carmela Silvestri ◽  
...  
Keyword(s):  
Multidrug Resistant ◽  
Vitro Activity ◽  
Immunocompromised Patients ◽  
In Vitro Activity ◽  
Beta Lactams ◽  
Gram Negative ◽  
Resistant Strains ◽  
Multidrug Resistant Pathogens ◽  
Gram Negative Organisms

ABSTRACT The in vitro activity of the histatin derivative P-113, alone or combined with eight antibiotics, was investigated against multidrug-resistant strains isolated from clinical specimens of immunocompromised patients with pneumonia. The gram-negative isolates were susceptible to P-113. S. aureus showed less susceptibility. Synergy was demonstrated when P-113 was combined with beta-lactams against gram-negative organisms.

scholarly journals S-649266, A Novel Siderophore Cephalosporin: In Vitro Activity Against Gram-Negative Bacteria Isolated in Japan Including Carbapenem-Resistant Strains

2015 ◽  
Vol 2 (suppl_1) ◽  
Author(s):  
Masakatsu Tsuji ◽  
Takahiro Yamaguchi ◽  
Rio Nakamura ◽  
Tsukasa Ito-Horiyama ◽  
Takafumi Sato ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Gram Negative Bacteria ◽  
In Vitro Activity ◽  
Gram Negative ◽  
Carbapenem Resistant ◽  
Resistant Strains

scholarly journals 728. Activity of Eravacycline Against Contemporary Gram-Negative Clinical Isolates From New York City Hospitals

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S326-S326
Author(s):  
Alejandro Iregui ◽  
Zeb Khan ◽  
David Landman ◽  
John M Quale
Keyword(s):  
New York ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Antibiotic Resistant ◽  
Gram Negative ◽  
E Coli ◽  
The Usa ◽  
Recent Collection

Abstract Background Antibiotic-resistant Gram-negative bacteria, including KPC-producing Enterobacteriaceae and carbapenem-resistant A. baumannii, have been problematic hospital pathogens in NYC and other areas. Eravacycline (ERV), a fluorocycline antibiotic released in the USA in 2018, has demonstrated in vitro activity against many of these strains. We tested the activity of ERV against a recent collection of clinical isolates from NYC hospitals. Methods For a 3-month period in 2017, all unique patient isolates of E. coli, K. pneumoniae, Enterobacter spp., and A. baumannii were collected from 7 hospitals in Brooklyn, NY. MICs were performed by broth microdilution for ERV and Tigecycline (TGC) and agar dilution for other antibiotics according to CLSI methodology. Cephalosporin-resistant isolates were screened by PCR for common carbapenemases. Results The susceptibility results for tetracycline and ERV are listed in the Table. Overall, 95% of the Enterobacteriaceae were inhibited by ≤ 0.5 μg/mL of ERV, the FDA-suggested breakpoint. Of 1,876 isolates of E. coli, 4 possessed KPC. ERV MICs for these 4 isolates were 0.125–0.25 μg/mL. Of 518 isolates of K. pneumoniae, 20 possessed KPC. The ERV MIC50 and MIC90 for these isolates were 1 and 1 μg/mL, respectively. Of 172 isolates of Enterobacter spp., 3 possessed KPC. ERV MICs for these 3 isolates were 0.5–1 μg/mL. Of 45 isolates of A. baumannii, 11 isolates possessed a carbapenemase (OXA23 in 8, OXA24 in 2, and KPC in 1). The ERV MIC50 and MIC90 for these isolates were 1 and 2 μg/mL, respectively. Overall, ERV MICs were two-fold lower than TGC MICs for A. baumannii. Conclusion ERV possesses significant in vitro activity against contemporary clinical isolates of Enterobacteriaceae and A. baumannii from NYC, including many carbapenemase producing strains. Disclosures All authors: No reported disclosures.

In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and Enterococci

1995 ◽  
Vol 21 (3) ◽  
pp. 169-173 ◽  
Author(s):  
Caroline C. Johnson ◽  
Linda Slavoski ◽  
Mary Schwartz ◽  
Phyllis May ◽  
Peter G. Pitsakis ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Antibiotic Resistant ◽  
Resistant Strains
Sign in / Sign up

Export Citation Format

Share Document